NHS Gene Therapy Restores Sight to Six-Year-Old Girl with Rare Eye Condition
A courageous six-year-old girl from Hertfordshire has experienced a remarkable restoration of her vision thanks to groundbreaking gene therapy provided by the National Health Service. Saffie Sandford, a vibrant youngster from Stevenage who adores Spider-Man, was diagnosed with the rare inherited eye disorder Leber's Congenital Amaurosis (LCA) at age five after her parents observed her difficulties with night vision.
Leber's Congenital Amaurosis is a genetic condition that prevents cells in the eye from producing a specific protein essential for normal vision. Children affected by LCA typically have severely limited vision in daylight and complete blindness in low-light conditions, with total sight loss often occurring by adulthood without intervention.
Diagnosis and Treatment Journey
Saffie's parents, Lisa and Tam, were devastated by the diagnosis, having been unaware they were carriers of the genetic mutation. "Saffie's diagnosis came as a huge shock to us," Lisa Sandford explained. "We'd never heard of the condition or knew we were carriers."
Following diagnostic tests at Moorfields Eye Hospital in London, Saffie was referred to Great Ormond Street Hospital for Children (GOSH) for pioneering treatment with Luxturna, a one-time gene therapy that injects a healthy copy of the defective gene directly into the eye. This represents the first approved treatment targeting one of the genetic causes of LCA.
Saffie underwent the procedure in her first eye during April 2025 and received treatment in her second eye the following September. Prior to this, she had worn glasses since age two to correct short-sightedness.
Life-Changing Results
The transformation has been profound. "Having the gene treatment has been life-changing," her mother described. "It's like someone waved a magic wand and restored her sight in the dark."
Before treatment, Saffie's condition severely restricted daily activities. "She was blind in the dark, which made daily activities challenging," Lisa recalled. "We were told that without the treatment, she would be blind by the age of 30."
Now, the family can participate in evening activities previously impossible, including trick-or-treating and dining out at restaurants. Saffie's peripheral vision in daylight has improved significantly, enhancing her ability to navigate hazards and excel academically. She can now engage in typical six-year-old pursuits like climbing frames with confidence.
"She's thriving and you wouldn't know she had the condition just by looking at her," her mother shared. "The results have been incredible, and we are eternally grateful that our little girl has been given her sight back. We know it might not last forever, but we feel fortunate every day that she has been given this chance."
Groundbreaking Research Findings
Researchers from Great Ormond Street Hospital and University College London have recently published significant findings demonstrating that Luxturna not only improves sight but also strengthens visual pathways during critical stages of brain development. Their study followed fifteen children treated with the gene therapy between 2020 and 2023, revealing enhanced visual pathway function in young patients with RPE65-related retinal disease.
The research team treated children ranging from just fifteen months old to twelve years, discovering that younger patients experienced more substantial improvements because treatment occurred during crucial developmental windows. To assess outcomes objectively, researchers employed pattern visual evoked potentials (VEPs), a painless test measuring signal transmission from retina to visual cortex that's particularly valuable for evaluating very young children or those with neurodevelopmental conditions.
Rob Henderson, consultant ophthalmologist at GOSH, emphasized the significance: "For the first time, we've been able to show objectively that gene therapy can strengthen the visual pathways in babies and young children who are living with this rare eye condition."
While researchers stop short of calling Luxturna a complete cure, they remain optimistic about long-term outcomes and continue gathering data. Henderson added, "This research highlights not only the potential of gene therapy to change what's possible for children with inherited retinal disease, but also the importance of developing age-appropriate outcome measures. Pattern VEPs could help set a new standard for how future paediatric gene therapy trials are assessed around the world."
The Sandford family's experience represents a beacon of hope for families affected by inherited retinal conditions, showcasing the transformative potential of NHS-funded advanced medical treatments.
